25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ADAP (Adaptimmune) Stock Analysis
Buy, Hold or Sell?

Let's analyze Adaptimmune together

I guess you are interested in Adaptimmune Therapeutics Plc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • ๐Ÿ“Š Fundamental Analysis (FA) โ€“ Adaptimmuneโ€™s Financial Insights
  • ๐Ÿ“ˆ Technical Analysis (TA) โ€“ Adaptimmuneโ€™s Price Targets

I'm going to help you getting a better view of Adaptimmune Therapeutics Plc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Adaptimmune Therapeutics Plc

I send you an email if I find something interesting about Adaptimmune Therapeutics Plc.

1. Quick Overview

1.1. Quick analysis of Adaptimmune (30 sec.)










1.2. What can you expect buying and holding a share of Adaptimmune? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.14
Expected worth in 1 year
$-0.37
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-0.23
Return On Investment
-86.8%

For what price can you sell your share?

Current Price per Share
$0.27
Expected price per share
$0.1951 - $0.3301
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Adaptimmune (5 min.)




Live pricePrice per Share (EOD)
$0.27
Intrinsic Value Per Share
$-6.95 - $-4.09
Total Value Per Share
$-7.09 - $-4.23

2.2. Growth of Adaptimmune (5 min.)




Is Adaptimmune growing?

Current yearPrevious yearGrowGrow %
How rich?-$37.4m$69.6m-$31.9m-84.9%

How much money is Adaptimmune making?

Current yearPrevious yearGrowGrow %
Making money-$17.4m-$40.9m$23.4m134.4%
Net Profit Margin-736.4%-5,659.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Adaptimmune (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#839 / 872

Most Revenue
#156 / 872

Most Profit
#616 / 872

Most Efficient
#675 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Adaptimmune?

Welcome investor! Adaptimmune's management wants to use your money to grow the business. In return you get a share of Adaptimmune.

First you should know what it really means to hold a share of Adaptimmune. And how you can make/lose money.

Speculation

The Price per Share of Adaptimmune is $0.2686. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Adaptimmune.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Adaptimmune, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.14. Based on the TTM, the Book Value Change Per Share is $-0.06 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.06 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Adaptimmune.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.18-66.8%-0.07-24.5%-0.15-57.5%-0.12-43.3%-0.13-47.8%-0.11-39.7%
Usd Book Value Change Per Share-0.19-69.2%-0.06-21.7%-0.06-20.9%-0.06-23.5%-0.04-15.7%-0.01-4.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.19-69.2%-0.06-21.7%-0.06-20.9%-0.06-23.5%-0.04-15.7%-0.01-4.5%
Usd Price Per Share0.20-0.67-1.02-1.01-2.80-5.17-
Price to Earnings Ratio-0.27--0.85--1.81--1.80--5.11--20.47-
Price-to-Total Gains Ratio-1.06--3.76--7.91-4.54--10.00--128.84-
Price to Book Ratio-1.40-4.12-6.70-4.76-4.80-7.04-
Price-to-Total Gains Ratio-1.06--3.76--7.91-4.54--10.00--128.84-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.2686
Number of shares3723
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.06-0.04
Usd Total Gains Per Share-0.06-0.04
Gains per Quarter (3723 shares)-217.03-156.94
Gains per Year (3723 shares)-868.12-627.77
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-868-8780-628-638
20-1736-17460-1256-1266
30-2604-26140-1883-1894
40-3472-34820-2511-2522
50-4341-43500-3139-3150
60-5209-52180-3767-3778
70-6077-60860-4394-4406
80-6945-69540-5022-5034
90-7813-78220-5650-5662
100-8681-86900-6278-6290

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%3.037.00.07.5%3.044.01.06.3%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%4.016.00.020.0%10.030.00.025.0%13.031.04.027.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.048.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%4.016.00.020.0%10.030.00.025.0%13.031.04.027.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Adaptimmune Therapeutics Plc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.186-0.058-69%-0.056-70%-0.063-66%-0.042-77%-0.012-93%
Book Value Per Share---0.1410.142-199%0.263-154%0.267-153%0.598-124%0.690-120%
Current Ratio--2.0172.968-32%3.006-33%3.298-39%5.644-64%6.395-68%
Debt To Asset Ratio--1.2370.909+36%0.775+60%0.791+56%0.609+103%0.409+203%
Debt To Equity Ratio---6.267-100%4.953-100%4.500-100%2.945-100%1.610-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value---83722756.000106215093.000-179%209081764.000-140%215337194.000-139%788385834.400-111%1464057980.350-106%
Eps---0.180-0.066-63%-0.155-14%-0.116-35%-0.128-28%-0.107-41%
Ev To Ebitda Ratio--0.491-0.689+241%-1.510+408%-4.205+957%-7.144+1556%-15.519+3263%
Ev To Sales Ratio---2.8730.878-427%38.414-107%16.387-118%202.387-101%267.142-101%
Free Cash Flow Per Share---0.251-0.104-59%-0.130-48%-0.125-50%-0.100-60%-0.087-65%
Free Cash Flow To Equity Per Share---0.347-0.081-77%-0.102-71%-0.104-70%-0.040-88%-0.003-99%
Gross Profit Margin--1.0000.992+1%1.014-1%1.0020%1.0010%1.0010%
Intrinsic Value_10Y_max---4.091----------
Intrinsic Value_10Y_min---6.946----------
Intrinsic Value_1Y_max---0.359----------
Intrinsic Value_1Y_min---0.537----------
Intrinsic Value_3Y_max---1.117----------
Intrinsic Value_3Y_min---1.762----------
Intrinsic Value_5Y_max---1.923----------
Intrinsic Value_5Y_min---3.138----------
Market Cap71192967.200+27%52215244.000176325843.000-70%270220514.000-81%266465610.667-80%742066084.400-93%1370080293.200-96%
Net Profit Margin---6.532-7.364+13%-56.594+766%-22.701+248%-28.119+330%-30.216+363%
Operating Margin---6.195-7.004+13%-61.461+892%-24.186+290%-29.532+377%-30.346+390%
Operating Ratio--7.2788.460-14%65.239-89%27.367-73%41.473-82%48.817-85%
Pb Ratio-1.902-36%-1.3954.122-134%6.695-121%4.761-129%4.796-129%7.040-120%
Pe Ratio-0.374-36%-0.274-0.850+210%-1.811+560%-1.798+556%-5.109+1763%-20.469+7361%
Price Per Share0.269+27%0.1970.665-70%1.020-81%1.005-80%2.800-93%5.169-96%
Price To Free Cash Flow Ratio-0.267-36%-0.196-0.242+23%-2.283+1065%-7.098+3521%-8.867+4423%-12.021+6032%
Price To Total Gains Ratio-1.445-36%-1.060-3.757+255%-7.906+646%4.537-123%-10.005+844%-128.835+12059%
Quick Ratio--1.6143.181-49%3.481-54%3.939-59%8.448-81%8.815-82%
Return On Assets---0.301-0.111-63%-0.144-52%-0.112-63%-0.103-66%-0.097-68%
Return On Equity----1.4400%-0.9750%-0.8900%-0.5950%-0.3570%
Total Gains Per Share---0.186-0.058-69%-0.056-70%-0.063-66%-0.042-77%-0.012-93%
Usd Book Value---37429000.00037670750.000-199%69667000.000-154%70863250.000-153%158628050.000-124%182893803.575-120%
Usd Book Value Change Per Share---0.186-0.058-69%-0.056-70%-0.063-66%-0.042-77%-0.012-93%
Usd Book Value Per Share---0.1410.142-199%0.263-154%0.267-153%0.598-124%0.690-120%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value---83722756.000106215093.000-179%209081764.000-140%215337194.000-139%788385834.400-111%1464057980.350-106%
Usd Eps---0.180-0.066-63%-0.155-14%-0.116-35%-0.128-28%-0.107-41%
Usd Free Cash Flow---66592000.000-27555988.750-59%-34561137.750-48%-33188958.833-50%-26542225.300-60%-23172574.170-65%
Usd Free Cash Flow Per Share---0.251-0.104-59%-0.130-48%-0.125-50%-0.100-60%-0.087-65%
Usd Free Cash Flow To Equity Per Share---0.347-0.081-77%-0.102-71%-0.104-70%-0.040-88%-0.003-99%
Usd Market Cap71192967.200+27%52215244.000176325843.000-70%270220514.000-81%266465610.667-80%742066084.400-93%1370080293.200-96%
Usd Price Per Share0.269+27%0.1970.665-70%1.020-81%1.005-80%2.800-93%5.169-96%
Usd Profit---47584000.000-17473750.000-63%-40956708.000-14%-28989736.000-39%-32907891.600-31%-27530903.737-42%
Usd Revenue--7285000.00044909750.000-84%4590002.250+59%22431084.083-68%14104700.450-48%10260076.475-29%
Usd Total Gains Per Share---0.186-0.058-69%-0.056-70%-0.063-66%-0.042-77%-0.012-93%
 EOD+6 -2MRQTTM+9 -28YOY+9 -283Y+7 -305Y+8 -2910Y+8 -29

3.3 Fundamental Score

Let's check the fundamental score of Adaptimmune Therapeutics Plc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.374
Price to Book Ratio (EOD)Between0-1-1.902
Net Profit Margin (MRQ)Greater than0-6.532
Operating Margin (MRQ)Greater than0-6.195
Quick Ratio (MRQ)Greater than11.614
Current Ratio (MRQ)Greater than12.017
Debt to Asset Ratio (MRQ)Less than11.237
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.301
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Adaptimmune Therapeutics Plc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.269
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Fundamental data was last updated by Penke on 2025-07-10 19:48:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitย Adaptimmune earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareย Adaptimmune to theย Biotechnology industry mean.
  • A Net Profit Margin of -653.2%ย means thatย $-6.53 for each $1ย in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Adaptimmune Therapeutics Plc:

  • The MRQ is -653.2%. The company is making a huge loss. -2
  • The TTM is -736.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-653.2%TTM-736.4%+83.2%
TTM-736.4%YOY-5,659.4%+4,923.0%
TTM-736.4%5Y-2,811.9%+2,075.5%
5Y-2,811.9%10Y-3,021.6%+209.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-653.2%-93.6%-559.6%
TTM-736.4%-140.9%-595.5%
YOY-5,659.4%-197.6%-5,461.8%
3Y-2,270.1%-248.5%-2,021.6%
5Y-2,811.9%-343.4%-2,468.5%
10Y-3,021.6%-496.2%-2,525.4%
4.3.1.2. Return on Assets

Shows howย efficientย Adaptimmune is using its assets to generate profit.

  • Above 5% is considered healthyย but always compareย Adaptimmune to theย Biotechnology industry mean.
  • -30.1% Return on Assets means thatย Adaptimmune generatedย $-0.30 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Adaptimmune Therapeutics Plc:

  • The MRQ is -30.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.1%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.1%TTM-11.1%-19.0%
TTM-11.1%YOY-14.4%+3.3%
TTM-11.1%5Y-10.3%-0.7%
5Y-10.3%10Y-9.7%-0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.1%-11.6%-18.5%
TTM-11.1%-11.6%+0.5%
YOY-14.4%-11.4%-3.0%
3Y-11.2%-11.8%+0.6%
5Y-10.3%-12.0%+1.7%
10Y-9.7%-13.7%+4.0%
4.3.1.3. Return on Equity

Shows how efficient Adaptimmune is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareย Adaptimmune to theย Biotechnology industry mean.
  • 0.0% Return on Equity means Adaptimmune generated $0.00ย for eachย $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Adaptimmune Therapeutics Plc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-144.0%+144.0%
TTM-144.0%YOY-97.5%-46.6%
TTM-144.0%5Y-59.5%-84.6%
5Y-59.5%10Y-35.7%-23.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--13.5%+13.5%
TTM-144.0%-14.9%-129.1%
YOY-97.5%-14.6%-82.9%
3Y-89.0%-16.8%-72.2%
5Y-59.5%-17.5%-42.0%
10Y-35.7%-19.9%-15.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Adaptimmune Therapeutics Plc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measuresย how efficient Adaptimmune is operatingย .

  • Measures how much profit Adaptimmune makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareย Adaptimmune to theย Biotechnology industry mean.
  • An Operating Margin of -619.5%ย means the company generated $-6.19 ย for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Adaptimmune Therapeutics Plc:

  • The MRQ is -619.5%. The company is operating very inefficient. -2
  • The TTM is -700.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-619.5%TTM-700.4%+80.9%
TTM-700.4%YOY-6,146.1%+5,445.7%
TTM-700.4%5Y-2,953.2%+2,252.8%
5Y-2,953.2%10Y-3,034.6%+81.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-619.5%-232.5%-387.0%
TTM-700.4%-250.5%-449.9%
YOY-6,146.1%-209.2%-5,936.9%
3Y-2,418.6%-234.1%-2,184.5%
5Y-2,953.2%-346.1%-2,607.1%
10Y-3,034.6%-477.5%-2,557.1%
4.3.2.2. Operating Ratio

Measures how efficient Adaptimmune is keepingย operating costsย low.

  • Below 1 is considered healthy (always compare toย Biotechnology industry mean).
  • An Operation Ratio of 7.28 means that the operating costs are $7.28 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Adaptimmune Therapeutics Plc:

  • The MRQ is 7.278. The company is inefficient in keeping operating costs low. -1
  • The TTM is 8.460. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ7.278TTM8.460-1.183
TTM8.460YOY65.239-56.779
TTM8.4605Y41.473-33.012
5Y41.47310Y48.817-7.345
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.2782.111+5.167
TTM8.4602.694+5.766
YOY65.2393.096+62.143
3Y27.3673.652+23.715
5Y41.4734.745+36.728
10Y48.8176.614+42.203
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Adaptimmune Therapeutics Plc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Adaptimmune is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toย Biotechnology industry mean).
  • A Current Ratio of 2.02ย means the company has $2.02 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Adaptimmune Therapeutics Plc:

  • The MRQ is 2.017. The company is able to pay all its short-term debts. +1
  • The TTM is 2.968. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.017TTM2.968-0.952
TTM2.968YOY3.006-0.038
TTM2.9685Y5.644-2.675
5Y5.64410Y6.395-0.752
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0173.661-1.644
TTM2.9683.846-0.878
YOY3.0064.140-1.134
3Y3.2984.688-1.390
5Y5.6445.746-0.102
10Y6.3956.147+0.248
4.4.3.2. Quick Ratio

Measures if Adaptimmune is able to pay off Short-term Debt but only usingย theย most liquid assets.

  • Above 1 is considered healthy butย always compareย Adaptimmune to theย Biotechnology industry mean.
  • A Quick Ratio of 1.61ย means the company can pay off $1.61 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Adaptimmune Therapeutics Plc:

  • The MRQ is 1.614. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.181. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.614TTM3.181-1.567
TTM3.181YOY3.481-0.300
TTM3.1815Y8.448-5.267
5Y8.44810Y8.815-0.367
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6142.848-1.234
TTM3.1813.169+0.012
YOY3.4813.786-0.305
3Y3.9394.311-0.372
5Y8.4485.703+2.745
10Y8.8156.368+2.447
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Adaptimmune Therapeutics Plc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %ย of Adaptimmuneย assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareย Adaptimmune to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.24ย means that Adaptimmune assets areย financed with 123.7% credit (debt) and the remaining percentage (100% - 123.7%)ย is financed by its owners/shareholders.ย 

Let's take a look of the Debt to Asset Ratio trends of Adaptimmune Therapeutics Plc:

  • The MRQ is 1.237. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 0.909. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ1.237TTM0.909+0.327
TTM0.909YOY0.775+0.135
TTM0.9095Y0.609+0.300
5Y0.60910Y0.409+0.200
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2370.329+0.908
TTM0.9090.349+0.560
YOY0.7750.331+0.444
3Y0.7910.340+0.451
5Y0.6090.349+0.260
10Y0.4090.379+0.030
4.5.4.2. Debt to Equity Ratio

Measures ifย Adaptimmune is able toย pay off its debts by usingย shareholders equity.

  • Below 2 is considered healthy butย always compareย Adaptimmune to theย Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Adaptimmune Therapeutics Plc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM6.267-6.267
TTM6.267YOY4.953+1.314
TTM6.2675Y2.945+3.322
5Y2.94510Y1.610+1.336
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.379-0.379
TTM6.2670.437+5.830
YOY4.9530.414+4.539
3Y4.5000.450+4.050
5Y2.9450.464+2.481
10Y1.6100.515+1.095
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measuresย how much money you payย for each share forย every $1 in earnings Adaptimmune generates.

  • Above 15 is considered overpriced butย always compareย Adaptimmune to theย Biotechnology industry mean.
  • A PE ratio of -0.27 means the investor is paying $-0.27ย for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Adaptimmune Therapeutics Plc:

  • The EOD is -0.374. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.274. Based on the earnings, the company is expensive. -2
  • The TTM is -0.850. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.374MRQ-0.274-0.100
MRQ-0.274TTM-0.850+0.576
TTM-0.850YOY-1.811+0.961
TTM-0.8505Y-5.109+4.259
5Y-5.10910Y-20.469+15.359
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.374-2.356+1.982
MRQ-0.274-2.077+1.803
TTM-0.850-2.574+1.724
YOY-1.811-3.760+1.949
3Y-1.798-3.773+1.975
5Y-5.109-6.193+1.084
10Y-20.469-6.876-13.593
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Adaptimmune Therapeutics Plc:

  • The EOD is -0.267. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.196. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.242. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.267MRQ-0.196-0.071
MRQ-0.196TTM-0.242+0.046
TTM-0.242YOY-2.283+2.041
TTM-0.2425Y-8.867+8.625
5Y-8.86710Y-12.021+3.155
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.267-3.246+2.979
MRQ-0.196-2.705+2.509
TTM-0.242-3.704+3.462
YOY-2.283-4.402+2.119
3Y-7.098-5.070-2.028
5Y-8.867-8.477-0.390
10Y-12.021-9.305-2.716
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofย Adaptimmune is to cheap or to expensiveย compared to its book value.

  • At or below 1 is considered healthyย (always compare to Biotechnology industry mean).
  • A PB ratio of -1.40 means the investor is paying $-1.40ย for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Adaptimmune Therapeutics Plc:

  • The EOD is -1.902. Based on the equity, the company is expensive. -2
  • The MRQ is -1.395. Based on the equity, the company is expensive. -2
  • The TTM is 4.122. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD-1.902MRQ-1.395-0.507
MRQ-1.395TTM4.122-5.517
TTM4.122YOY6.695-2.573
TTM4.1225Y4.796-0.674
5Y4.79610Y7.040-2.244
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.9022.038-3.940
MRQ-1.3951.843-3.238
TTM4.1222.125+1.997
YOY6.6952.442+4.253
3Y4.7612.492+2.269
5Y4.7963.652+1.144
10Y7.0404.311+2.729
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Adaptimmune Therapeutics Plc.

4.8.1. Institutions holding Adaptimmune Therapeutics Plc

Institutions are holding 44.163% of the shares of Adaptimmune Therapeutics Plc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31EcoR1 Capital, LLC10.33910.32022740407000
2025-03-31Long Focus Capital Management, LLC8.9630.156123756687326229415.918
2025-03-31Two Seas Capital LP7.74550.127420529685569453938.3855
2025-03-31NEA Management Company, LLC6.44390.25911707977800
2025-03-31Mpm Asset Management, LLC2.01311.51385335715-219746-3.9555
2025-03-31MPM Oncology Impact Management LP1.84660.16584894344-201568-3.9555
2025-03-31Morgan Stanley - Brokerage Accounts1.0247027159471391083104.9982
2025-03-31Rock Springs Capital Management LP0.9370.028248346800
2025-03-31Acadian Asset Management LLC0.83690.0012221821522182150
2025-03-31Renaissance Technologies Corp0.68430.00051813860-712664-28.2073
2025-03-31FMR Inc0.662101754889-9617-0.545
2025-03-31Bank of America Corp0.432801147013-1715317-59.9273
2025-03-31UBS Group AG0.382101012740870996614.4853
2025-03-31JPMorgan Chase & Co0.33290882331-34610-3.7745
2025-03-31Rathbone Brothers PLC0.16330.000443281800
2025-03-31State Street Corp0.15890421292212135.3022
2025-03-31Clear Harbor Asset Management, LLC0.09080.00382407252222001199.4602
2025-03-31Two Sigma Advisers, LLC0.0780.0001206732135997192.2627
2025-03-31BlackRock Inc0.0693018368600
2025-03-31Key Client Fiduciary Advisors, LLC0.05660.0135150150-105209-41.2004
Total 43.26092.5899114664145+10817806+9.4%

4.9.2. Funds holding Adaptimmune Therapeutics Plc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-02-28Edinburgh Worldwide Ord1.99290.3128528220200
2024-11-30Galileo - Biotech Innovation Fund S USD0.28391.458575245800
2025-05-30SPDRยฎ Portfolio Developed Wld ex-US ETF0.10760.000328517900
2025-05-31SEI International Equity F (SIT)0.08520.0018225793-20951-8.491
2025-05-30SPDRยฎ S&Pยฎ International Small Cap ETF0.05370.006114244100
2025-05-30Fidelity Enhanced Small Cap ETF0.04610.00212220500
2025-05-30Invesco NASDAQ Future Gen 200 ETF0.02940.30637803100
2025-05-31Top Class Healthcare FI0.02830.18057500000
2025-04-30Fidelity Nasdaq Composite Index0.02530.000167032-72769-52.0518
2025-05-31Club Innovation Santรฉ0.01710.02954535100
2025-03-31Northern Small Cap Core I0.00640.00091689100
2025-03-31NT Quality SCC US Fund - L0.00360.001954800
2025-03-31NT Quality Small Cap Core0.00360.0011954800
2024-09-30Baillie Gifford US Discovery Instl0.00240.3044638500
2025-02-28Guggenheim Active Allocation Fund0.0001027300
Total 2.68562.60537118337-93720-1.3%

5.3. Insider Transactions

Insiders are holding 0.631% of the shares of Adaptimmune Therapeutics Plc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-01-17Elliot NorrySELL55840.58
2025-01-15Cintia PiccinaSELL129910.57
2025-01-15William C Bertrand JrSELL98030.57
2025-01-13Elliot NorrySELL123920.59
2025-01-13William C Bertrand JrSELL97390.59
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Total Stockholder Equity 24,37571,89996,274-16,28579,989-68,14011,849-49,278-37,429
Net Invested Capital  24,37596,853121,2288,626129,854-67,76862,086-74,104-12,018
Net Interest Income  1,345-495850137987-92166-1,037-971



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets158,072
Total Liabilities195,501
Total Stockholder Equity-37,429
 As reported
Total Liabilities 195,501
Total Stockholder Equity+ -37,429
Total Assets = 158,072

Assets

Total Assets158,072
Total Current Assets102,998
Long-term Assets55,074
Total Current Assets
Cash And Cash Equivalents 41,054
Short-term Investments 18,509
Net Receivables 4,382
Inventory 11,759
Other Current Assets 27,294
Total Current Assets  (as reported)102,998
Total Current Assets  (calculated)102,998
+/-0
Long-term Assets
Property Plant Equipment 48,941
Intangible Assets 3,806
Long-term Assets Other 2,327
Long-term Assets  (as reported)55,074
Long-term Assets  (calculated)55,074
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities51,072
Long-term Liabilities144,429
Total Stockholder Equity-37,429
Total Current Liabilities
Short-term Debt 4,627
Accounts payable 5,701
Other Current Liabilities 22,599
Total Current Liabilities  (as reported)51,072
Total Current Liabilities  (calculated)32,927
+/- 18,145
Long-term Liabilities
Long term Debt 25,411
Capital Lease Obligations 23,295
Long-term Liabilities Other 4,371
Long-term Liabilities  (as reported)144,429
Long-term Liabilities  (calculated)53,077
+/- 91,352
Total Stockholder Equity
Common Stock2,099
Retained Earnings -1,141,571
Accumulated Other Comprehensive Income -4,412
Other Stockholders Equity 1,106,455
Total Stockholder Equity (as reported)-37,429
Total Stockholder Equity (calculated)-37,429
+/-0
Other
Capital Stock2,099
Cash and Short Term Investments 59,563
Common Stock Shares Outstanding 257,027
Current Deferred Revenue12,444
Liabilities and Stockholders Equity 158,072
Net Debt -17,759
Net Invested Capital -12,018
Net Working Capital 51,926
Property Plant and Equipment Gross 138,069
Short Long Term Debt Total 23,295



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-30
> Total Assets 
1,812
0
0
54,333
55,518
0
137,715
0
300,300
297,310
285,821
261,560
239,560
222,644
234,515
265,980
284,279
301,377
281,147
247,068
211,299
309,625
276,736
270,440
239,521
208,251
181,543
285,241
512,201
479,022
451,142
411,581
389,793
353,528
469,545
419,799
388,270
332,202
328,916
288,081
342,984
296,638
282,616
258,010
321,702
317,436
245,963
158,072
158,072245,963317,436321,702258,010282,616296,638342,984288,081328,916332,202388,270419,799469,545353,528389,793411,581451,142479,022512,201285,241181,543208,251239,521270,440276,736309,625211,299247,068281,147301,377284,279265,980234,515222,644239,560261,560285,821297,310300,3000137,715055,51854,333001,812
   > Total Current Assets 
0
264
0
52,933
54,088
0
134,868
48,836
294,700
282,556
263,047
238,561
218,182
199,544
198,751
222,932
237,744
253,904
230,183
195,663
161,654
261,605
231,095
200,301
175,133
146,970
120,489
227,761
458,087
426,733
398,152
359,293
337,344
300,450
415,458
359,461
321,165
264,139
255,370
213,748
261,771
219,368
207,552
186,903
253,770
244,214
188,169
102,998
102,998188,169244,214253,770186,903207,552219,368261,771213,748255,370264,139321,165359,461415,458300,450337,344359,293398,152426,733458,087227,761120,489146,970175,133200,301231,095261,605161,654195,663230,183253,904237,744222,932198,751199,544218,182238,561263,047282,556294,70048,836134,868054,08852,93302640
       Cash And Cash Equivalents 
248
-264
0
50,179
51,274
0
101,434
-48,836
228,800
217,076
194,263
163,766
150,894
140,440
158,779
170,559
121,998
145,326
84,043
53,375
42,312
153,081
68,379
49,917
34,574
39,409
50,412
86,429
122,359
78,466
56,882
32,432
50,453
42,918
149,948
89,539
97,811
79,001
108,033
119,866
76,969
90,059
143,991
140,670
211,810
116,741
91,139
41,054
41,05491,139116,741211,810140,670143,99190,05976,969119,866108,03379,00197,81189,539149,94842,91850,45332,43256,88278,466122,35986,42950,41239,40934,57449,91768,379153,08142,31253,37584,043145,326121,998170,559158,779140,440150,894163,766194,263217,076228,800-48,836101,434051,27450,1790-264248
       Short-term Investments 
0
528
0
0
55,000
0
24,807
97,672
55,200
54,838
54,620
62,337
55,031
47,064
22,694
33,114
98,023
86,532
124,218
108,459
86,716
84,652
136,755
118,241
98,832
63,451
39,130
110,000
296,629
321,442
311,335
285,512
234,917
197,202
219,632
214,679
160,278
120,669
96,572
45,688
127,738
71,669
2,947
2,982
2,979
69,349
60,466
18,509
18,50960,46669,3492,9792,9822,94771,669127,73845,68896,572120,669160,278214,679219,632197,202234,917285,512311,335321,442296,629110,00039,13063,45198,832118,241136,75584,65286,716108,459124,21886,53298,02333,11422,69447,06455,03162,33754,62054,83855,20097,67224,807055,000005280
       Net Receivables 
0
0
0
27
1,889
0
8,628
0
10,600
10,508
744
1
1,000
1,000
1,480
107
1,406
4,063
206
21,188
18,605
2,031
192
22,488
30,773
31,726
19,284
23,004
26,746
13,921
20,724
31,141
39,913
45,087
752
42,888
49,425
53,534
38,087
1,715
40,925
42,694
46,919
28,892
23,765
38,614
15,982
4,382
4,38215,98238,61423,76528,89246,91942,69440,9251,71538,08753,53449,42542,88875245,08739,91331,14120,72413,92126,74623,00419,28431,72630,77322,4881922,03118,60521,1882064,0631,4061071,4801,0001,000174410,50810,60008,62801,88927000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
135
0
0
1,192
0
0
0
3,760
3,843
2,993
1,190
1,087
862
1,755
1,522
1,459
952
1,521
2,488
2,086
1,576
1,591
1,285
746
10,077
1,327
8,052
1,279
1,310
1,334
1,290
1,329
0
0
1,874
7,320
11,759
11,7597,3201,874001,3291,2901,3341,3101,2798,0521,32710,0777461,2851,5911,5762,0862,4881,5219521,4591,5221,7558621,0871,1902,9933,8433,7600001,1920013500000000000
   > Long-term Assets 
0
-264
0
1,400
1,431
0
2,847
-48,836
5,600
14,754
22,774
22,999
21,378
23,100
35,764
43,048
46,535
47,473
50,964
51,405
49,645
48,020
45,641
70,139
64,388
61,281
61,054
57,480
54,114
52,289
52,990
52,288
52,449
53,078
54,087
60,338
67,105
68,063
73,546
74,333
81,213
77,270
75,064
71,107
67,932
73,222
57,794
55,074
55,07457,79473,22267,93271,10775,06477,27081,21374,33373,54668,06367,10560,33854,08753,07852,44952,28852,99052,28954,11457,48061,05461,28164,38870,13945,64148,02049,64551,40550,96447,47346,53543,04835,76423,10021,37822,99922,77414,7545,600-48,8362,84701,4311,4000-2640
       Property Plant Equipment 
209
0
0
1,400
1,431
0
2,847
0
5,400
11,575
13,225
13,845
13,444
15,086
27,899
35,092
38,922
39,771
40,679
41,235
39,472
38,137
36,118
60,165
55,229
52,204
51,857
48,172
45,912
45,718
46,658
46,065
46,435
50,170
51,369
57,834
64,780
65,783
71,535
72,312
77,519
73,873
71,708
67,725
64,070
65,290
51,218
48,941
48,94151,21865,29064,07067,72571,70873,87377,51972,31271,53565,78364,78057,83451,36950,17046,43546,06546,65845,71845,91248,17251,85752,20455,22960,16536,11838,13739,47241,23540,67939,77138,92235,09227,89915,08613,44413,84513,22511,5755,40002,84701,4311,40000209
       Intangible Assets 
0
0
0
0
0
0
0
0
200
179
305
1,140
1,010
1,127
1,268
1,310
1,431
1,374
1,337
1,238
1,196
1,515
1,473
1,529
2,066
2,274
2,198
2,366
2,134
1,970
1,730
1,619
1,382
1,191
1,000
788
612
568
442
443
463
384
330
524
996
4,283
3,880
3,806
3,8063,8804,2839965243303844634434425686127881,0001,1911,3821,6191,7301,9702,1342,3662,1982,2742,0661,5291,4731,5151,1961,2381,3371,3741,4311,3101,2681,1271,0101,14030517920000000000
       Other Assets 
0
0
0
0
0
0
0
0
178
3,171
11,949
9,154
7,934
8,014
7,865
7,956
7,613
7,702
10,285
8,932
8,977
8,368
8,050
8,445
7,093
6,803
6,999
6,942
6,068
4,601
4,602
4,604
4,632
1,717
1,718
1,716
1,713
1,712
1,569
0
3,231
3,013
0
0
0
0
0
0
0000003,0133,23101,5691,7121,7131,7161,7181,7174,6324,6044,6024,6016,0686,9426,9996,8037,0938,4458,0508,3688,9778,93210,2857,7027,6137,9567,8658,0147,9349,15411,9493,17117800000000
> Total Liabilities 
3,968
0
0
51,974
53,108
0
45,850
0
41,000
46,632
27,889
42,614
42,569
42,640
68,373
57,654
54,784
72,392
78,163
55,806
46,197
33,470
29,851
50,785
52,530
60,568
57,905
99,204
104,616
102,816
109,915
102,424
111,854
112,545
263,585
256,654
246,353
218,865
247,038
204,205
216,333
208,509
243,103
233,635
225,428
237,447
234,114
195,501
195,501234,114237,447225,428233,635243,103208,509216,333204,205247,038218,865246,353256,654263,585112,545111,854102,424109,915102,816104,61699,20457,90560,56852,53050,78529,85133,47046,19755,80678,16372,39254,78457,65468,37342,64042,56942,61427,88946,63241,000045,850053,10851,974003,968
   > Total Current Liabilities 
3,968
0
0
51,974
53,108
0
45,850
0
26,700
33,177
27,889
19,838
20,137
22,661
40,270
31,912
30,253
68,572
74,314
51,922
42,310
29,566
24,437
23,435
28,293
37,401
34,341
29,816
38,559
34,899
39,073
31,307
41,416
41,137
62,541
66,151
73,632
66,080
64,501
63,631
76,125
75,146
72,788
66,411
82,073
63,457
64,527
51,072
51,07264,52763,45782,07366,41172,78875,14676,12563,63164,50166,08073,63266,15162,54141,13741,41631,30739,07334,89938,55929,81634,34137,40128,29323,43524,43729,56642,31051,92274,31468,57230,25331,91240,27022,66120,13719,83827,88933,17726,700045,850053,10851,974003,968
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
5,270
7,594
9,418
16,448
13,828
0
0
0
0
0
0
0
2,217
4,676
4,674
2,493
5,180
4,986
5,238
2,773
2,845
5,844
4,534
4,640
2,735
5,114
4,948
2,728
2,842
4,752
5,081
5,384
5,250
10,586
4,175
4,709
4,627
4,6274,7094,17510,5865,2505,3845,0814,7522,8422,7284,9485,1142,7354,6404,5345,8442,8452,7735,2384,9865,1802,4934,6744,6762,217000000013,82816,4489,4187,5945,27000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,217
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000002,21700000000000000000000000
       Accounts payable 
1,916
0
0
990
1,012
0
45,850
0
26,700
4,667
7,884
2,440
2,474
2,496
11,350
5,177
4,577
2,489
8,378
5,051
4,131
3,907
4,083
5,391
4,344
5,535
6,357
7,066
8,766
4,030
6,389
4,116
6,977
4,784
8,113
7,017
15,991
6,905
4,753
5,187
14,713
13,922
8,128
6,587
7,513
9,069
8,692
5,701
5,7018,6929,0697,5136,5878,12813,92214,7135,1874,7536,90515,9917,0178,1134,7846,9774,1166,3894,0308,7667,0666,3575,5354,3445,3914,0833,9074,1315,0518,3782,4894,5775,17711,3502,4962,4742,4407,8844,66726,700045,85001,012990001,916
       Other Current Liabilities 
514
0
0
50,984
43,601
0
0
0
24,744
4,052
20,005
5,321
7,723
10,651
15,514
15,110
13,372
17,424
21,460
19,192
21,457
20,926
20,354
15,827
16,257
24,509
23,363
15,912
21,343
21,996
27,079
22,263
23,684
25,717
27,589
31,627
30,059
33,605
33,500
33,298
25,242
21,750
23,521
23,050
25,557
31,504
38,830
22,599
22,59938,83031,50425,55723,05023,52121,75025,24233,29833,50033,60530,05931,62727,58925,71723,68422,26327,07921,99621,34315,91223,36324,50916,25715,82720,35420,92621,45719,19221,46017,42413,37215,11015,51410,6517,7235,32120,0054,05224,74400043,60150,98400514
   > Long-term Liabilities 
0
0
0
0
1,013
0
45,850
0
14,300
13,455
26,500
22,776
22,432
19,979
28,103
25,742
24,531
3,820
3,849
3,884
3,887
3,904
5,414
27,350
24,237
23,167
23,564
69,388
66,057
67,917
70,842
71,117
70,438
71,408
201,044
190,503
172,721
152,785
182,537
140,574
140,208
133,363
170,315
167,224
143,355
173,990
169,587
144,429
144,429169,587173,990143,355167,224170,315133,363140,208140,574182,537152,785172,721190,503201,04471,40870,43871,11770,84267,91766,05769,38823,56423,16724,23727,3505,4143,9043,8873,8843,8493,82024,53125,74228,10319,97922,43222,77626,50013,45514,300045,85001,0130000
       Other Liabilities 
0
0
0
0
0
0
0
0
14,311
13,422
26,503
22,776
22,432
19,335
28,103
25,742
24,531
3,820
3,849
3,884
3,887
3,904
5,414
571
571
568
598
47,559
45,243
46,827
49,904
51,220
50,715
47,704
177,896
167,283
151,086
132,859
162,188
0
118,618
112,843
0
0
0
0
0
0
000000112,843118,6180162,188132,859151,086167,283177,89647,70450,71551,22049,90446,82745,24347,5595985685715715,4143,9043,8873,8843,8493,82024,53125,74228,10319,33522,43222,77626,50313,42214,31100000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
14,885
0
24,962
22,776
22,432
19,335
24,962
22,394
20,754
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000020,75422,39424,96219,33522,43222,77624,962014,88500000000
> Total Stockholder Equity
0
-2,296
0
2,359
2,410
0
91,864
2,295
259,300
250,678
234,993
218,946
196,991
180,004
166,142
208,326
229,495
228,985
202,984
191,262
165,102
276,155
246,885
219,655
186,991
147,683
123,638
186,037
407,585
376,206
341,227
309,157
277,939
240,983
205,960
163,145
141,917
113,337
81,878
83,876
126,651
88,129
39,513
24,375
96,274
79,989
11,849
-37,429
-37,42911,84979,98996,27424,37539,51388,129126,65183,87681,878113,337141,917163,145205,960240,983277,939309,157341,227376,206407,585186,037123,638147,683186,991219,655246,885276,155165,102191,262202,984228,985229,495208,326166,142180,004196,991218,946234,993250,678259,3002,29591,86402,4102,3590-2,2960
   Retained Earnings -1,141,571-1,093,987-1,019,772-1,002,155-1,071,676-1,023,173-975,256-929,655-908,266-909,302-880,052-838,631-794,111-743,846-704,988-662,587-623,519-585,756-549,143-513,711-483,831-455,664-426,300-386,998-345,911-318,499-282,326-287,568-244,063-231,630-204,367-203,489-183,274-161,492-146,078-127,584-105,489-89,913-44,939-47,1000-34,0840-32,263-31,574000
   Accumulated Other Comprehensive Income 
0
-2,296
0
33,629
187
0
182
2,295
253,000
122,079
-8,139
-10,684
-13,011
-13,788
-14,249
-14,366
-16,854
-20,055
-21,641
-27,136
-14,419
-12,813
-9,763
-13,096
-8,199
-10,025
-7,264
-9,590
-8,805
-8,494
-10,048
-10,224
-10,385
-10,098
-11,142
-9,313
-1,043
6,683
-875
-1,785
-3,092
102
-3,748
-2,720
-3,412
-5,136
-1,902
-4,412
-4,412-1,902-5,136-3,412-2,720-3,748102-3,092-1,785-8756,683-1,043-9,313-11,142-10,098-10,385-10,224-10,048-8,494-8,805-9,590-7,264-10,025-8,199-13,096-9,763-12,813-14,419-27,136-21,641-20,055-16,854-14,366-14,249-13,788-13,011-10,684-8,139122,079253,0002,295182018733,6290-2,2960
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
334,437
336,904
339,188
341,200
405,165
448,985
452,553
455,401
461,603
466,229
570,355
574,208
577,722
581,245
583,065
585,623
678,319
928,777
932,518
935,706
941,569
949,575
954,732
959,611
965,227
980,204
985,312
0
0
0
0
0
0
0
0
0
0
0000000000985,312980,204965,227959,611954,732949,575941,569935,706932,518928,777678,319585,623583,065581,245577,722574,208570,355466,229461,603455,401452,553448,985405,165341,200339,188336,904334,43700000000000
   Treasury Stock000000000000000000000000000000000000000000000000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue178,032
Cost of Revenue-70
Gross Profit177,962177,962
 
Operating Income (+$)
Gross Profit177,962
Operating Expense-246,722
Operating Income-68,760-68,760
 
Operating Expense (+$)
Research Development149,060
Selling General Administrative80,805
Selling And Marketing Expenses506
Operating Expense246,722230,371
 
Net Interest Income (+$)
Interest Income6,596
Interest Expense-3,348
Other Finance Cost-0
Net Interest Income3,248
 
Pretax Income (+$)
Operating Income-68,760
Net Interest Income3,248
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-67,238-70,282
EBIT - interestExpense = -67,243
-67,238
-67,466
Interest Expense3,348
Earnings Before Interest and Taxes (EBIT)-63,895-63,890
Earnings Before Interest and Taxes (EBITDA)-52,665
 
After tax Income (+$)
Income Before Tax-67,238
Tax Provision-3,576
Net Income From Continuing Ops-70,814-70,814
Net Income-70,814
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses246,792
Total Other Income/Expenses Net1,522-3,248
 

Technical Analysis of Adaptimmune
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Adaptimmune. The general trend of Adaptimmune is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Adaptimmune's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Adaptimmune Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Supportย is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistanceย is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Adaptimmune Therapeutics Plc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.31 < 0.3264 < 0.3301.

The bearish price targets are: 0.2258 > 0.2035 > 0.1951.

Know someone who trades $ADAP? Share this with them.๐Ÿ‘‡

Adaptimmune Therapeutics Plc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theย moving averageย of the selected period.

  • Moving averages are laggingย trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Adaptimmune Therapeutics Plc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Adaptimmune Therapeutics Plc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theย momentumย of theย selected period based on two moving averages.

  • MACD is aย lagging momentumย indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Adaptimmune Therapeutics Plc.

Adaptimmune Therapeutics Plc Daily Moving Average Convergence/Divergence (MACD) ChartAdaptimmune Therapeutics Plc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Adaptimmune Therapeutics Plc. The current adx is .

Adaptimmune Therapeutics Plc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Showsย the current trend.
  • Showsย potential entry signals.
  • Showsย ย potential exit signals.
  • Can be used to placeย trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Adaptimmune Therapeutics Plc.

Adaptimmune Therapeutics Plc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumย indicator, meaning the signals are instant.
  • Rangesย between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Adaptimmune Therapeutics Plc.

Adaptimmune Therapeutics Plc Daily Relative Strength Index (RSI) ChartAdaptimmune Therapeutics Plc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Comparesย a certain price to multiple prices ranging over time.

  • Leadingย momentumย indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Rangesย between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Adaptimmune Therapeutics Plc.

Adaptimmune Therapeutics Plc Daily Stochastic Oscillator ChartAdaptimmune Therapeutics Plc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,ย the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Adaptimmune Therapeutics Plc.

Adaptimmune Therapeutics Plc Daily Commodity Channel Index (CCI) ChartAdaptimmune Therapeutics Plc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Adaptimmune Therapeutics Plc.

Adaptimmune Therapeutics Plc Daily Chande Momentum Oscillator (CMO) ChartAdaptimmune Therapeutics Plc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

ย Shows the current price relative to the highest high over the last 14 days.
ย 

  • Lagging momentum indicator
  • Ranging between 0 andย -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Adaptimmune Therapeutics Plc.

Adaptimmune Therapeutics Plc Daily Williams %R ChartAdaptimmune Therapeutics Plc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldย 

Score

Let's take a look at the Bollinger Bands of Adaptimmune Therapeutics Plc.

Adaptimmune Therapeutics Plc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Adaptimmune Therapeutics Plc.

Adaptimmune Therapeutics Plc Daily Average True Range (ATR) ChartAdaptimmune Therapeutics Plc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

ย Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Adaptimmune Therapeutics Plc.

Adaptimmune Therapeutics Plc Daily On-Balance Volume (OBV) ChartAdaptimmune Therapeutics Plc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Adaptimmune Therapeutics Plc.

Adaptimmune Therapeutics Plc Daily Money Flow Index (MFI) ChartAdaptimmune Therapeutics Plc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Adaptimmune Therapeutics Plc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-05RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-10BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-05BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-07MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-09MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-07-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Adaptimmune Therapeutics Plc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Adaptimmune Therapeutics Plc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.269
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Adaptimmune with someone you think should read this too:
  • Are you bullish or bearish on Adaptimmune? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Adaptimmune? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Adaptimmune Therapeutics Plc

I send you an email if I find something interesting about Adaptimmune Therapeutics Plc.


Comments

How you think about this?

Leave a comment

Stay informed about Adaptimmune Therapeutics Plc.

Receive notifications about Adaptimmune Therapeutics Plc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.